BCL-2 but not FOXP1, is an adverse risk factor in immunochemotherapy treated non-germinal center diffuse large B-cell lymphomas

Dettagli Bibliografici
Autori principali: Nyman, H, Jerkeman, M, Karjalainen-Lindsberg, M, Banham, A, Enblad, G, Leppa, S
Natura: Conference item
Pubblicazione: 2008